Timothy Youngquist Trust reports 12.75M CHRS shares

Coherus Oncology, Inc. reporting person Timothy G. Youngquist 2020 Irrevocable Trust amended its Schedule 13G to state it beneficially owns 12,750,800 shares of common stock, representing 8.3% of the class based on April 16, 2026 outstanding shares.

Rhea-AI Filing Summary

Coherus Oncology, Inc. reporting person Timothy G. Youngquist 2020 Irrevocable Trust amended its Schedule 13G to state it beneficially owns 12,750,800 shares of common stock, representing 8.3% of the class based on April 16, 2026 outstanding shares. The filing notes inclusion of 460,000 shares issuable under call options exercisable within 60 days for purposes of Rule 13d-3. The amendment (No. 2) corrects information in a prior amendment and is signed by the trust's manager on May 15, 2026.

Insights

Corporate Governance Analyst

Trust reports a notable passive stake with optioned shares included.

The Timothy G. Youngquist 2020 Irrevocable Trust is disclosed as beneficial owner of 12,750,800 shares, equal to 8.3% of the outstanding common stock calculated from the proxy's April 16, 2026 figure. The filing explicitly includes 460,000 shares underlying call options deemed outstanding under Rule 13d-3.

Because this is an amended Schedule 13G, the position is presented as passive in the signer certification. Subsequent disclosures or amendments would show any change in classification or additional holdings.

Investor Relations Specialist

Amendment clarifies ownership but does not signal active control intent.

The amendment corrects prior Amendment No. 1 and states the trust's voting and dispositive powers are sole and total for the reported shares (12,750,800). The filing attaches an explicit calculation basis using 154,217,609 shares outstanding as of April 16, 2026.

Cash‑flow treatment or plans for disposition are not included; future filings will be the source for any changes in position or disposition activity.

Key Figures

Beneficially owned shares: 12,750,800 shares Percent of class: 8.3% Shares outstanding (basis): 154,217,609 shares +2 more

5 metrics

Beneficially owned shares 12,750,800 shares Amount reported by the Trust in this amendment

Percent of class 8.3% Calculated using 154,217,609 shares outstanding as of April 16, 2026

Shares outstanding (basis) 154,217,609 shares Outstanding shares cited from the Definitive Proxy Statement as of April 16, 2026

Call options included 460,000 shares Underlying call options exercisable within 60 days counted under Rule 13d-3

Filing signature date 05/15/2026 Date the amendment was signed by the manager

Key Terms

Schedule 13G/A, beneficially owned, Rule 13d-3, Irrevocable Trust

4 terms

Schedule 13G/A regulatory

"Amendment No. 2 to Schedule 13G (cover wording)"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Amount beneficially owned: See Item 9 of the Cover Page"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Rule 13d-3 regulatory

"Includes 460,000 shares of common stock underlying call options ... for purposes of Rule 13d-3"

Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.

Irrevocable Trust other

"Timothy G. Youngquist 2020 Irrevocable Trust, dated 2020"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does the Timothy G. Youngquist 2020 Irrevocable Trust report in CHRS?

The Trust reports 12,750,800 shares, representing 8.3% of common stock based on April 16, 2026 outstanding shares, as stated in the amendment.

Does the filing include optioned shares in the ownership total for CHRS?

Yes. The amendment includes 460,000 shares underlying call options that are exercisable within 60 days, which are counted under Rule 13d-3.

Why was Amendment No. 2 filed for this Schedule 13G/A for CHRS?

Amendment No. 2 was filed to correct certain information in Amendment No. 1; the filing states it explicitly corrects prior amendment details and restates ownership.

What voting and dispositive powers does the Trust report for CHRS shares?

The Trust reports sole voting power and sole dispositive power over all 12,750,800 shares, as shown on the cover page entries in the filing.

What outstanding share count does the filing use to calculate the Trust's percentage in CHRS?

The percentage is based on 154,217,609 shares outstanding as of April 16, 2026, cited from the issuer's Definitive Proxy Statement on Schedule 14A.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 10:04 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Coherus Oncology, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

19249H103

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 19249H103

1

Names of Reporting Persons

Timothy G. Youngquist 2020 Irrevocable Trust

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FLORIDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 12,750,800.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 12,750,800.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,750,800.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.3 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage reported is based on 154,217,609 shares of the Issuer's common stock outstanding as of April 16, 2026, as reported in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 20, 2026. The shares reported herein are held by the Timothy G. Youngquist 2020 Irrevocable Trust, dated 2020, as amended and/or restated (the "Trust"), of which Trista Kragh is a trustee. Includes 460,000 shares of common stock underlying call options that constitute a right to acquire shares within 60 days for purposes of Rule 13d-3. For purposes of calculating the Reporting Person's percentage of class, such underlying shares are deemed outstanding. This Amendment No. 2 is filed solely to correct certain information in Amendment No. 1.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Coherus Oncology, Inc.
(b)	Address of issuer's principal executive offices: 333 Twin Dolphin Drive, Suite 600, Redwood City, CALIFORNIA, 94065
Item 2.
(a)	Name of person filing: Timothy G. Youngquist 2020 Irrevocable Trust
(b)	Address or principal business office or, if none, residence: 15581 Pine Ridge Road, Fort Myers, FL 33908
(c)	Citizenship: See Item 4 of the Cover Page.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 19249H103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 of the Cover Page.
(b)	Percent of class: See Item 11 of the Cover Page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 of the Cover Page.
	(ii) Shared power to vote or to direct the vote: See Item 6 of the Cover Page.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 of the Cover Page.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 of the Cover Page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Timothy G. Youngquist 2020 Irrevocable Trust

Signature:	Nolan Rheam
Name/Title:	Manager
Date:	05/15/2026